ࡱ>  l \pThe Free Software Foundation B=PF0*8X@"1 Helvetica1Courier1 Courier New1 Courier New1 Helvetica$#,##0_);($#,##0)$#,##0_);[Red]($#,##0)$#,##0.00_);($#,##0.00)$#,##0.00_);[Red]($#,##0.00)-**_($* #,##0_);_($* (#,##0);_($* "-"_);_(@_)*)'_(* #,##0_);_(* (#,##0);_(* "-"_);_(@_)5,2_($* #,##0.00_);_($* (#,##0.00);_($* "-"??_);_(@_)2+/_(* #,##0.00_);_(* (#,##0.00);_(* "-"??_);_(@_)2$#,##0.00;[Red]$#,##0.003$#,##0.00;[Red]($#,##0.00)4$#,##0;[Red]($#,##00)50.00%;[Red](0.00%)6 0%;[Red](0%)7#,##0.00;[Red](#,##0.00)8#,##0;[Red](#,##0)                + ) , *   Ј ~~ ؈ ~~#؈ ~~ ؈ ~~8#܈ ~~4#܈ ~~<#܈ ~~3#܈ ~~7#܈ ~~"؈ ~~83ffff̙̙3f3fff3f3f33333f33k THERAPEUTICSMD INC NA NA (1) 2 Balance Sheet 9NA (2)}VIncome Statement ^NA (3) Cash Flows NA (4)NOTE 4 INVENTORY"NOTE 5 OTHER CURRENT ASSETS5NOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS&7NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)&NOTE 8 OTHER CURRENT LIABILITIE NOTE 9 NET LOSS PER SHAREsNOTES TO UNAUDITED (2)#NOTES TO UNAUDITED (3)6Operating Lease9ATX001HR&SResearch and Development Expens&cThree months ended September 30:rOperating ExpensesKOperating Expen (1)&Nine months ended September 30 30 Operating Expenses&30 Operating Ex (1)&xSummary of Uses and Sources of hItem 6 Exhibits&xCERTIFICATION OF CHIEF EXECUTIV"CERTIFICATION OF CHIEF (1)&CERTIFICATION OF CHIEF FINANCIA"CERTIFICATION OF CHIEF (2)&SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1) l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#NANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 6} +      TherapeuticsMD, Inc. 10-Q 11/07/2017THERAPEUTICSMD, INC.Nevada 87-02335355 -(State or Other Jurisdiction of Incorporation, $(I.R.S. Employer Identification No.) or Organization)  2 *6800 Broken Sound Parkway NW, Third Floor, (561) 961-1900 Boca Raton, FL 334870((Address of Principal Executive Offices)#(Issuer?s Telephone Number)$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,_|vjBU5=PF0*8X> @ l  @  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 7} !      TherapeuticsMD, Inc. 10-Q 11/07/2017 N/A!Large accelerated filer ?Accelerated filer ? Non-accelerated filer ?# Smaller reporting company ?6 . (Do not check if a smaller reporting company)! Emerging growth company ?  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$[,{7vN=PF0*8X> @  l  .,1  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNA Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } y } :} $ }  .     TherapeuticsMD, Inc. 10-Q 11/07/2017 N/A Page& PART I - FINANCIAL INFORMATION         Item. 1 Financial Statements         3 +Consolidated Balance Sheets as of September ~ 2*30, 2017 (Unaudited) and December 31, 2016-%Consolidated Statements of Operations~ 5-for the Three and Nine Months Ended September1)30, 2017 (Unaudited) and 2016 (Unaudited)-%Consolidated Statements of Cash Flows~ /'for the Nine Months Ended September 30,-%2017 (Unaudited) and 2016 (Unaudited)2*Notes to Consolidated Financial Statements~ Item 2.,$Management?s Discussion and Analysis~ V80of Financial Condition and Results of OperationsItem 3.0(Quantitative and Qualitative Disclosures~ about Market RisksD5 l{;f*s76L_#f* !"#$%&'()*+,-  Item 4. Controls and Procedures ~ !!!!!#"Part II - OTHER INFORMATION""#####$$Item 1.$Legal Proceedings$~ $%%%%%&&Item 1A.& Risk Factors&~ &'''''((Item 6.(Exhibits(~ ()*$+____________________________1,)Created by Morningstar Document Research.0-(http://documentresearch.morningstar.com/ Ah)[ th@=PF0*8X> @*--,,++""  l  9  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1)NA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 1      TherapeuticsMD, Inc. 10-Q 11/07/2017 Balance Sheet-%THERAPEUTICSMD, INC. AND SUBSIDIARIES# CONSOLIDATED BALANCE SHEETS  $ ____________________________1 )Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/"}q@ =PF0*8X> @ l  6KU  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetIncome StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 8} $ } y} $ } y} $ 6                                 TherapeuticsMD, Inc. 10-Q 11/07/2017 N/ASeptember 30, 2017December 31, 2016    (Unaudited)            ASSETS  Current Assets:         Cash ~ [#  ~ V4\ -%Accounts receivable, net of allowance~  ~ n7/for doubtful accounts of $377,929 and $376,374, respectively Inventory~ 6N~ AOther current assets~ 6~ RTotal current assets~ Um%~  @5544330000     l  $^  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)NA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 1      TherapeuticsMD, Inc. 10-Q 11/07/2017Income Statement-%THERAPEUTICSMD, INC. AND SUBSIDIARIES- %CONSOLIDATED STATEMENTS OF OPERATIONS  (Unaudited)  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,zn= =PF0*8X> @ l  ,0z  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income Statement Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0} $ }  } $ } y}  $ } y} $ } y} $ ,     TherapeuticsMD, Inc. 10-Q 11/07/2017 N/AThree Months Ended  Nine Months Ended    September 30,    September 30,   ~   ~   ~   ~                 Revenues, net ~    ~ Q  ~ N  ~ ~                  Cost of goods sold~ :*~ K  ~  |  ~ v( Gross profit~ ~ W  ~  橇  ~  `     Operating expenses:     *"Sales, general, and administration~ 2~   ~  `   ~ hY Research and development~  ߈~   ~  V]t  ~ vFe %Depreciation and amortization~ L~ 2x  ~  >   ~ ~%Total operating expense~ l~    ~  v  ~      Operating loss~ v~ *N  ~  f3  ~        Other income:     Miscellaneous income~ 6 ~ ڵ  ~  J  ~ ^:Accreted interest ?~ N&  ~  Nx  ~ zTotal other income~ 6 ~ &  ~  w  ~      Loss before taxes~ ~ N*   ~    ~ A     DXl{VGhr0Wo !"#$%&'()*+" Provision for income taxes   ?    ?    ?    ? !!!!!!!!!! ! ! ! ! !!!"Net loss"~ """~ "N* "" ~ " " " ~ "A"########## # # # # ###-$%Net loss per share, basic and diluted$$Q뱿$$$p= ף$$ $ HzGѿ$ $ $(\տ$%%%%%%%%%% % % % % %%%0&(Weighted average number of common shares&&~ &1&&&~ &ތ.&& & ~ & ~^w0& & &~ &.&' outstanding($)____________________________1*)Created by Morningstar Document Research.0+(http://documentresearch.morningstar.com/sJ-1=PF0*8X> @++**))$$$$$$ $$"""""" ""          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3)NA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 1      TherapeuticsMD, Inc. 10-Q 11/07/2017 Cash Flows-%THERAPEUTICSMD, INC. AND SUBSIDIARIES- %CONSOLIDATED STATEMENTS OF CASH FLOWS  (Unaudited)  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$,tC=PF0*8X> @ l  0f  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } U5} $ }  } $ } } $ 0                                 TherapeuticsMD, Inc. 10-Q 11/07/2017 N/ANine Months Ended   September 30, 2017   September 30, 2016        , $CASH FLOWS FROM OPERATING ACTIVITIES         Net loss ~   ~ A 0 (Adjustments to reconcile net loss to net        0(cash flows used in operating activities:$Depreciation of fixed assets~ b~ )!Amortization of intangible assets~ 1~ Z'Provision for doubtful accounts~ N~   Share-based compensation~ ^{3~ 04,Changes in operating assets and liabilities:Accounts receivable~ 6~  Inventory~ R~ Other current assets~ =~ j0Accounts payable~ ^.?~ C!Other current liabilities~ n5~ ^*-%Net cash used in operating activities~ ~ n!=,$CASH FLOWS FROM INVESTING ACTIVITIES Patent costs~ (~ * Purchase of fixed assets~ ~ 7#Payment of security deposit ?~ $-%Net cash used in investing activities~ v~ LDl{:n~* gja`T ! " # $ % & ' ( ) * + , - . /          ,!$CASH FLOWS FROM FINANCING ACTIVITIES!!!!!!!!/"'Proceeds from sale of common stock, net""~ "nWY"""~ "i' "#of costs*$"Proceeds from exercise of warrants$$~ $^$$$~ $"S$)%!Proceeds from exercise of options%%~ % %%%~ %;%1&)Net cash provided by financing activities&&~ &0N&&&~ & &'''''''''(Increase in cash((~ (f(((~ (f(!)Cash, beginning of period))~ )V4\)))~ )\m)*Cash, end of period*~ *[#**~ *,#*+,$-____________________________1.)Created by Morningstar Document Research.0/(http://documentresearch.morningstar.com/$,,mY61(}=PF0*8X> @R //..--****     l  Ȱ  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ } $} $ }  } $                    TherapeuticsMD, Inc. 10-Q 11/07/2017NOTE 4 INVENTORY September 30, December 31,  ~   ~  Finished product ~ 6N  ~ 6@   Raw material   ?   ~ R  TOTAL INVENTORY ~ 6N  ~ A  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznMk_S+=PF0*8X> @Z        l  f  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0.} $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 11/07/2017#NOTE 5 OTHER CURRENT ASSETS September 30, December 31,  ~   ~ # Prepaid manufacturing costs ~ R=  ~ < ) !Prepaid sales and marketing costs  ~      ?  Prepaid insurance  ~ 7:   ~ U& . &Prepaid research and development costs   ?   ~  Prepaid consulting ?~  Prepaid vendor deposits~ "N~ ^Other prepaid costs~ V~ ""TOTAL OTHER CURRENT ASSETS~ 6~ R$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2{oc7&|T=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ }  } $ }  } $                         TherapeuticsMD, Inc. 10-Q 11/07/2017NOTE 6 FIXED ASSETS September 30, December 31,  ~   ~  Accounting system ~ `  ~ `   Equipment  ~ B   ~ :"   Computer hardware  ~ N   ~ N  Furniture and fixtures  ~    ~  Leasehold improvements~ P~ P~ &/~ - Accumulated depreciation~ ~ TOTAL FIXED ASSETS~  Y~ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2wkIOCK=PF0*8X> @Z      l  0  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } a/} $ }  } $ }  }  $ } y} $ }  } $      TherapeuticsMD, Inc. 10-Q 11/07/2017 NOTE 7 INTANGIBLE ASSETSSeptember 30, 2017   Gross Carrying Amount   Accumulated Amortization   Net   Weighted- Average            Amount   Remaining Amortization                Period (yrs.)% Amortizing intangible assets:                 OPERA ? software patent ~ >  ~ 2  ~ nv   ~ 2 .&Development costs of corporate website~ ~~ f    ?   n/a/'Approved hormone therapy drug candidate~ 6L~   ~  6B  .@patents.&Hormone therapy drug candidate patents~ 6Y ?  ~  6Y   n/a (pending))!Non-amortizing intangible assets:     Multiple trademarks~ bK  ?  ~  bK    indefinite Total~ ~  ~  6  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:] ~rf$G h\P(=PF0*8X> @        l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETSNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } a/} $ }  } $ }  }  $ }  } $ }  } $      TherapeuticsMD, Inc. 10-Q 11/07/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSDecember 31, 2016   Gross Carrying Amount   Accumulated Amortization   Net   Weighted- Average            Amount   Remaining Amortization                Period (yrs.)% Amortizing intangible assets:                 OPERA ? software patent ~ >  ~   ~ ֍    )@ .&Development costs of corporate website~ ~~ f    ?   n/a/'Approved hormone therapy drug candidate~ 2B~   ~  N}<  ~ Bpatents.&Hormone therapy drug candidate patents~ N|I ?  ~  N|I   n/a (pending))!Non-amortizing intangible assets:     Multiple trademarks~ Q  ?  ~  Q    indefinite Total~ ~ : ~  Rْ  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/:x nbVJ ,hMA5 =PF0*8X> @        l  -  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATED!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } } $      TherapeuticsMD, Inc. 10-Q 11/07/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS Year Ending Estimated  December 31,    Amortization  2017(3 months)  ~    ~   ~   ~   ~   ~   ~  ~ ~  Thereafter~ ^1$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/.wnbVJZv*=PF0*8X> @j        l     dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)NOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 0} $ } y} $ } y} $                             TherapeuticsMD, Inc. 10-Q 11/07/2017( NOTE 8 OTHER CURRENT LIABILITIES September 30, December 31,  ~   ~ $ Accrued clinical trial costs ~ B!  ~ 0N / 'Accrued payroll, bonuses and commission  ~ ^   ~ Š  costs$ Accrued compensated absences  ~ .$:   ~ f( ,$Accrued legal and accounting expense~ c~  )!Accrued sales and marketing costs~ 6~ (Other accrued expenses~ x~  0(Allowance for wholesale distributor fees~ n~ zAccrued royalties~ ~ .)!Allowance for coupons and returns~ &[J~ 0 Accrued rent~ ~ ^ 'TOTAL OTHER CURRENT LIABILITIES~ ‹~ VV$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/: vj^1iR9,u=PF0*8X> @Z      l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } m} $ } } $ } } $                     TherapeuticsMD, Inc. 10-Q 11/07/2017!NOTE 9 NET LOSS PER SHARENine Months Ended    September 30,  ~   ~    Stock options  ~ 0   ~   Warrants  ~ .   ~ n    ~ ^Q   ~ z $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/*h}qe$6*=PF0*8X> @:    l  *#  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } U} m} $ } m      TherapeuticsMD, Inc. 10-Q 11/07/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTSNine Months Ended   September 30,   September 30, ~  ~  Risk-free interest rate  1.84-2.01%   1.13-1.70%  Volatility  61.56-63.95%   70.26-71.22% Term (in years) 5.5-6.25   6.00-6.25Dividend yield 0.00% 0.00%$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|nbVJ!H^RF=PF0*8X> @" l  5  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } a/} $ } }  $ } U} $      TherapeuticsMD, Inc. 10-Q 11/07/2017<4NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS1)Number of Shares Underlying Stock Options'Weighted Average Exercise Price  Weighted   Aggregate           Average   Intrinsic Value            Remaining            Contractual            Life in Years$ Balance at December 31, 2016  ~ 0   {Gz @    333333@  ~ ]l Granted~ Tq= ףp@      Exercised~ (\@     ~ Expired/Forfeited~ Gz@     %Balance at September 30, 2017~ 0RQ@   @  ~ [ /'Vested and Exercisable at September 30,~ 333333 @   ffffff@  ~ bri ~ &Unvested at September 30, 2017~ 6ףp= @   333333!@  ~ r$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8 nbVJU { ;t=PF0*8X> @     l  @  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3) TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } I"} $ }  } $      TherapeuticsMD, Inc. 10-Q 11/07/2017Operating Lease!Years Ending December 31, 2017 (3 months)  ~   ~    ~ j: ~    ~ B ~    ~ C ~    ~ ^9 $Total minimum lease payments~  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,|{o5C7+=PF0*8X> @*  l  'PR  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $}  } m} <} m}  '     TherapeuticsMD, Inc. 10-Q 11/07/2017TX-001HR6.Replenish Trial Co-Primary Efficacy Endpoints:0 (Mean Change in Frequency and Severity of4 ,Hot Flashes Per Week Versus Placebo at Weeks% 4 and 12, VMS-MITT Population            Estradiol/Progesterone 1 mg/100 mg 0.5 mg/100 mg 0.5 mg/50 mg 0.25 mg/50 mgPlacebo (n = 141) (n = 149) (n = 147) (n = 154) (n = 135) Frequency%Week 4 P-value versus placebo9v??5^I ?MbP? ?&Week 12 P-value versus placeboMb`? ?Severity%Week 4 P-value versus placeboX9v?{Gzt?Dl?? ?&Week 12 P-value versus placebo;On?~jt? ?0(Replenish Trial Primary Safety Endpoint:6.Incidence of Consensus Endometrial Hyperplasia2*or Malignancy up to 12 months, EndometrialSafety Population?D] lv<_ |+kf-w !"#$%&      !Endometrial Hyperplasia! 0% (0/280)! 0% (0/303)! 0% (0/306)! 0% (0/274)! 0% (0/92)"#$$____________________________1%)Created by Morningstar Document Research.0&(http://documentresearch.morningstar.com/ x(=PF0*8X> @Z &&%%$$    l  b  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $} $ }  } $ }  }  $ } } $ }  } $      TherapeuticsMD, Inc. 10-Q 11/07/2017)!Research and Development ExpensesThree Months Ended  Nine Months Ended    September 30,    September 30,  ~   ~   ~   ~     (000s)   (000s)   TX 001-HR ~ /  ~ y  ~   ~ 6   TX 002-HR   ?    ?    ?    ?  TX 004-HR~ ~ (  ~  Rb  ~ x&Other research and development~ ~ :C  ~  H  ~ f Total~ d~ " ~  ze  ~ J     $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2 ui]+v=PF0*8X> @             l  Kq  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development ExpensOperating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } a} $ } U} $ }  }  $ } } $                         TherapeuticsMD, Inc. 10-Q 11/07/2017aYThree months ended September 30, 2017 compared with three months ended September 30, 2016Three Months Ended       September 30,  ~   ~    Change    (000s)   Revenues, net ~ E  ~ V  ~   Cost of goods sold  ~     ~ V   ~  Operating expenses~ !~   ~  V Operating loss~ B~ bw  ~  "_ Other income, net~ ~   ~   Net loss~ ~ &y ~  J^ $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2{I=1% K3=PF0*8X> @z          l  ~  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 11/07/2017Operating ExpensesThree Months Ended    September 30,  ~   ~  & Research and development costs   YA@ %   fffffH@ %. &Human resource related costs including   @@ %   L4@ %$ salaries, benefits and taxes2*Sales and marketing costs, excluding human~ F %,@ %resource costs/'Professional fees for legal, accounting@ %@ %and consulting Other operating expensesffffff"@ %ffffff%@ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4Oxl* iA:."=PF0*8X> @:    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating Expenses!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 6} $ }  } $ }  }  $ } } $                            TherapeuticsMD, Inc. 10-Q 11/07/2017Operating ExpensesThree Months Ended       September 30,  ~   ~    Change    (000s) & Research and development costs ~ d  ~ "  ~ v 0 (Human resources related costs, including  ~ :]   ~ 6]   ~  $salaries, benefits and taxes5-Sales and marketing, excluding human resource~ n1~ A  ~    costs/'Professional fees for legal, accounting~ ~   ~  6 and consulting Other operating expenses~ ~ .1  ~    Total operating expenses~ !~  ~  V $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/85 xlS|pd<=PF0*8X> @z          l  &  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } $ }  } $ }  }  $ } } $                         TherapeuticsMD, Inc. 10-Q 11/07/2017_WNine months ended September 30, 2017 compared with nine months ended September 30, 2016Nine Months Ended       September 30,  ~   ~    Change    (000s)   Revenues, net ~   ~ V  ~ b  Cost of goods sold  ~    ~ R6   ~  Operating expenses~ ~   ~  6B  Operating loss~ ҕ~ >  ~  nN Other income, net~  ~ J  ~   Net loss~ ڜ~  ~  K $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/2}K?3'N1~=PF0*8X> @z          l  u  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $} $ }  } $                          TherapeuticsMD, Inc. 10-Q 11/07/201730 Operating ExpensesNine Months Ended    September 30,  ~   ~  & Research and development costs   333333A@ %   33333K@ %/ 'Human resource related costs, including   333333:@ %  ~ Z %$ salaries, benefits and taxes2*Sales and marketing costs, excluding humanfffff8@ %#@ %resource costs/'Professional fees for legal, accountingffffff@ %ffffff@ %and consulting Other operating expenses @ %333333 @ %$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/4Rui(jB7+=PF0*8X> @:    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 2} $ }  } $ }  }  $ } U} $                            TherapeuticsMD, Inc. 10-Q 11/07/201730 Operating ExpensesNine Months Ended       September 30,  ~   ~    Change    (000s) & Research and development costs ~ ze  ~ J  ~ 2 0 (Human resources related costs, including  ~    ~ v   ~  $salaries, benefits and taxes2*Sales and marketing costs, excluding human~ :~ y  ~  j resource costs/'Professional fees for legal, accounting~ z?~ ~8  ~   and consulting Other operating expenses~ W~ c  ~    Total operating expenses~ ~  ~  6B $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/8= uiQ th\4=PF0*8X> @z          l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } 1} $                      TherapeuticsMD, Inc. 10-Q 11/07/2017-%Summary of (Uses) and Sources of CashNine Months Ended    September 30,  ~   ~     (000s) - %Net cash used in operating activities ~ *  ~  - %Net cash used in investing activities ~   ~  1)Net cash provided by financing activities~ "n~ `$____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/,[|}qeYY_=PF0*8X> @r         l  #  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of !CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } y } $ } a} $ } 6 #     TherapeuticsMD, Inc. 10-Q 11/07/2017Item 6. ExhibitsExhibit Date Description 333333$@  September 25, 2017 - %Underwriting Agreement by and between    . &the Company and J.P. Morgan Securities     LLC (1) 31.1*  November 7, 2017 0 (Certification of Chief Executive Officer    5 -pursuant to Rule 13a-14(a) and Rule 15d-14(a) 31.2*November 7, 20170(Certification of Chief Financial Officer5-pursuant to Rule 13a-14(a) and Rule 15d-14(a) 32.1*November 7, 20175-Section 1350 Certification of Chief ExecutiveOfficer 32.2*November 7, 20175-Section 1350 Certification of Chief FinancialOfficer101.INS* n/aXBRL Instance Document101.SCH* n/a/'XBRL Taxonomy Extension Schema Document101.CAL* n/a4,XBRL Taxonomy Extension Calculation LinkbaseDocument101.DEF* n/a3+XBRL Taxonomy Extension Definition LinkbaseInstance Document101.LAB* n/a.&XBRL Taxonomy Extension Label LinkbaseInstance Document101.PRE* n/a,$XBRL Taxonomy Extension Presentation"Linkbase Instance DocumentD lznA:y[z6w R !"$ ____________________________1!)Created by Morningstar Document Research.0"(http://documentresearch.morningstar.com/ (=PF0*8X> @""!!  l  /  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 ExhibitsCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } } 8 /     TherapeuticsMD, Inc. 10-Q 11/07/20170(CERTIFICATION OF CHIEF EXECUTIVE OFFICER (a)-%Designed such disclosure controls and  - %procedures, or caused such disclosure  . &controls and procedures to be designed  6 .under our supervision, to ensure that material  / 'information relating to the registrant,  0 (including its consolidated subsidiaries,2*is made known to us by others within those0(entities, particularly during the period/'in which this report is being prepared; (b)5-Designed such internal control over financial2*reporting, or caused such internal control/'over financial reporting to be designed4,under our supervision, to provide reasonable.&assurance regarding the reliability of/'financial reporting and the preparation5-of financial statements for external purposes-%in accordance with generally acceptedaccounting principles; (c)7/Evaluated the effectiveness of the registrant?s.&disclosure controls and procedures and0(presented in this report our conclusions1)about the effectiveness of the disclosure1)controls and procedures, as of the end of/'the period covered by this report basedDN lznbV w%@Ul"=c !"#$%&'()*+,-.   on such evaluation; and! !(d)2!*Disclosed in this report any change in the""4",registrant?s internal control over financial##7#/reporting that occurred during the registrant?s$$4$,most recent fiscal quarter (the registrant?s%%6%.fourth fiscal quarter in the case of an annual&&-&%report) that has materially affected,''5'-or is reasonably likely to materially affect,((.(&the registrant?s internal control over)) )financial reporting; and*+$,____________________________1-)Created by Morningstar Document Research.0.(http://documentresearch.morningstar.com/"t$/K=PF0*8X> @..--,, l  `  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIV!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } } $      TherapeuticsMD, Inc. 10-Q 11/07/20170(CERTIFICATION OF CHIEF EXECUTIVE OFFICERNovember 7, 2017/s/ Robert G. Finizio  Robert G. Finizio  Chief Executive Officer % (Principal Executive Officer)  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&}@znbV th@=PF0*8X> @2    l  /  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)CERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } $ } } 8 /     TherapeuticsMD, Inc. 10-Q 11/07/20170(CERTIFICATION OF CHIEF FINANCIAL OFFICER (a)-%Designed such disclosure controls and  - %procedures, or caused such disclosure  . &controls and procedures to be designed  6 .under our supervision, to ensure that material  / 'information relating to the registrant,  0 (including its consolidated subsidiaries,2*is made known to us by others within those0(entities, particularly during the period/'in which this report is being prepared; (b)5-Designed such internal control over financial2*reporting, or caused such internal control/'over financial reporting to be designed4,under our supervision, to provide reasonable.&assurance regarding the reliability of/'financial reporting and the preparation5-of financial statements for external purposes-%in accordance with generally acceptedaccounting principles; (c)7/Evaluated the effectiveness of the registrant?s.&disclosure controls and procedures and0(presented in this report our conclusions1)about the effectiveness of the disclosure1)controls and procedures, as of the end of/'the period covered by this report basedDN lznbV w%@Ul"=c !"#$%&'()*+,-.   on such evaluation; and! !(d)2!*Disclosed in this report any change in the""4",registrant?s internal control over financial##7#/reporting that occurred during the registrant?s$$4$,most recent fiscal quarter (the registrant?s%%6%.fourth fiscal quarter in the case of an annual&&-&%report) that has materially affected,''5'-or is reasonably likely to materially affect,((.(&the registrant?s internal control over)) )financial reporting; and*+$,____________________________1-)Created by Morningstar Document Research.0.(http://documentresearch.morningstar.com/"t$/K=PF0*8X> @..--,, l  $  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIA!SECTION 1350 CERTIFICATION OF CSECTION 1350 CE (1)U } } } $      TherapeuticsMD, Inc. 10-Q 11/07/20170(CERTIFICATION OF CHIEF FINANCIAL OFFICERNovember 7, 2017 /s/ Daniel A. Cartwright  Daniel A. Cartwright  Chief Financial Officer 4 ,(Principal Financial and Accounting Officer)   $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/(TznbV kSG;=PF0*8X> @2    l    dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)SECTION 1350 CE (1)U } } } $      TherapeuticsMD, Inc. 10-Q 11/07/2017=5SECTION 1350 CERTIFICATION OF CHIEF EXECUTIVE OFFICER November 7, 2017 /s/ Robert G. Finizio   Robert G. Finizio  Chief Executive Officer  $____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/&m@maUI1xP=PF0*8X> @*   l  "  dMbP?_*+%,&٭e2?'٭e2?(٭e2?)٭e2?",D/??#THERAPEUTICSMD INCNANA (1) Balance SheetNA (2)Income StatementNA (3) Cash FlowsNA (4)NOTE 4 INVENTORYNOTE 5 OTHER CURRENT ASSETSNOTE 6 FIXED ASSETSNOTE 7 INTANGIBLE ASSETS!NOTES TO UNAUDITED CONSOLIDATEDNOTES TO UNAUDITED (1)!NOTE 8 OTHER CURRENT LIABILITIENOTE 9 NET LOSS PER SHARENOTES TO UNAUDITED (2)NOTES TO UNAUDITED (3)Operating Lease TX001HR!Research and Development Expens!Three months ended September 30Operating ExpensesOperating Expen (1)!Nine months ended September 30 30 Operating Expenses30 Operating Ex (1)!Summary of Uses and Sources of Item 6 Exhibits!CERTIFICATION OF CHIEF EXECUTIVCERTIFICATION OF CHIEF (1)!CERTIFICATION OF CHIEF FINANCIACERTIFICATION OF CHIEF (2)!SECTION 1350 CERTIFICATION OF CU } } } $      TherapeuticsMD, Inc. 10-Q 11/07/2017=5SECTION 1350 CERTIFICATION OF CHIEF FINANCIAL OFFICERNovember 7, 2017 /s/ Daniel A. Cartwright  Daniel A. Cartwright  Chief Financial Officer  $ ____________________________1)Created by Morningstar Document Research.0(http://documentresearch.morningstar.com/$G,maUIb=PF0*8X> @*    Root Entry FBook  -#  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~